Xenon reports 2025 net loss of $345.9M; Phase 3 X-TOLE2 data expected in March 2026

Xenon Pharmaceuticals Inc.

2025-FY EPS reported -$4.36 revenue$7,500,000

Net loss $345.9M in 2025 vs $234.3M in 2024; R&D expense rose to $300.9M on azetukalner Phase 3 trials.
Pro forma cash $716M (incl. $130M ATM in Q1 2026) extends runway into H2 2027.
Phase 3 X-TOLE2 topline data for azetukalner in focal onset seizures due first half of March 2026.
NDA submission for azetukalner in FOS planned H2 2026; 5 additional Phase 3 studies in epilepsy and depression enrolling.
Early-stage pipeline: Phase 1 data for XEN1701 (NaV1.7) and XEN1120 (KV7) pain candidates expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.